Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PHIL™ (Precipitating Hydrophobic Injectable Liquid) Middle Meningeal Artery Embolization (MMAE) for First-Line Treatment of Chronic Subdural Hematoma (cSDH) IDE Trial (PHILFIRST)

NCT07576998 is registered in ClinicalTrials.gov with Microvention-Terumo, Inc. as lead sponsor.

NCT NCT07576998
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07576998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PHIL™ (Precipitating Hydrophobic Injectable Liquid) Middle Meningeal Artery Embolization (MMAE) for First-Line Treatment of Chronic Subdural Hematoma (cSDH) IDE Trial (PHILFIRST)
Lead sponsor
Microvention-Terumo, Inc.
Phase
Not applicable
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
May 31, 2031
Enrollment
475 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic subdural hematomas